Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Dezember 2025 10:00 ET | Quelle: 4D Path

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform
02. Juni 2025 10:30 ET | Quelle: 4D Path

4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population

4D Path QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate
20. Mai 2025 10:00 ET | Quelle: 4D Path

4D Path Expands Scientific Advisory Board with Global Leaders in Oncology and Pathology

Renowned experts in oncology and pathology join forces on 4D Path SAB to accelerate the impact of digital treatment prediction biomarkers